Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone

Jörg B. Engel, Gunhild Keller, Andrew V Schally, Gabor L. Toller, Kate Groot, Alexandre Havt, Patricia Armatis, Marta Zarandi, Jozsef L. Varga, Gabor Halmos

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Antagonists of GHRH are being developed for the treatment of various cancers. In this study we investigated in vivo and in vitro the effects of the GHRH antagonist MZ-J-7-118 and its mechanism of action in HEC-1A human endometrial cancer. Treatment of nude mice bearing HEC-1A xenografts with 10 μg/d MZ-J-7-118 for 6 wk significantly inhibited the volume of HEC-1A tumors by 43%, tumor weight by 40% compared with controls and prolonged the tumor doubling time from 18.7 ± 1.4 to 25.4 ± 3.8 d. Administration of 20 μg MZ-J-7-118, sc, twice a day significantly (P < 0.05) decreased HEC-1A growth, as evidenced by a 57.9% decrease in tumor volume, a 50.7% reduction in tumor weight, and the extension of tumor doubling time from 17.5 ± 2.8 to 36.4 ± 6.5 d. Therapy with GHRH antagonists significantly decreased serum IGF-I levels in experiment 1, and significantly increased tumoral IGF-I levels in experiment 2 in treated mice. Levels of IGF-II and vascular endothelial growth factor-A in tumors were not changed. Specific high affinity binding sites for GHRH were found on HEC-1A tumor membranes using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42. MZ-J-7-118 displaced radiolabeled JV-1-42 with an IC50 of 0.13 ± 0.04 nM. The expression of mRNA for GHRH and splice variants of the GHRH receptor in HEC-1A tumors was demonstrated by real-time RT-PCR analysis. HEC-1A cells cultured in vitro secreted GHRH into the medium. The GHRH antagonist MZ-J-7-118 inhibited the growth of HEC-1A cells in vitro. Our results indicate that GHRH antagonists can reduce the growth of human endometrial cancer and could be used as an alternative adjuvant therapy for the management of endometrial cancer.

Original languageEnglish
Pages (from-to)3614-3621
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number6
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Endometrial Neoplasms
Tumors
Growth
Tumor Burden
Neoplasms
Insulin-Like Growth Factor I
Bearings (structural)
Insulin-Like Growth Factor II
Complementary Therapies
Heterografts
Nude Mice
Vascular Endothelial Growth Factor A
Inhibitory Concentration 50
Real-Time Polymerase Chain Reaction
Cultured Cells
Binding Sites
MZ-J-7-118
Ligands
Assays

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. / Engel, Jörg B.; Keller, Gunhild; Schally, Andrew V; Toller, Gabor L.; Groot, Kate; Havt, Alexandre; Armatis, Patricia; Zarandi, Marta; Varga, Jozsef L.; Halmos, Gabor.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 6, 01.06.2005, p. 3614-3621.

Research output: Contribution to journalArticle

Engel, JB, Keller, G, Schally, AV, Toller, GL, Groot, K, Havt, A, Armatis, P, Zarandi, M, Varga, JL & Halmos, G 2005, 'Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone', Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3614-3621. https://doi.org/10.1210/jc.2004-2179
Engel, Jörg B. ; Keller, Gunhild ; Schally, Andrew V ; Toller, Gabor L. ; Groot, Kate ; Havt, Alexandre ; Armatis, Patricia ; Zarandi, Marta ; Varga, Jozsef L. ; Halmos, Gabor. / Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 6. pp. 3614-3621.
@article{d5665108959b471281b73b3b9ce41537,
title = "Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone",
abstract = "Antagonists of GHRH are being developed for the treatment of various cancers. In this study we investigated in vivo and in vitro the effects of the GHRH antagonist MZ-J-7-118 and its mechanism of action in HEC-1A human endometrial cancer. Treatment of nude mice bearing HEC-1A xenografts with 10 μg/d MZ-J-7-118 for 6 wk significantly inhibited the volume of HEC-1A tumors by 43{\%}, tumor weight by 40{\%} compared with controls and prolonged the tumor doubling time from 18.7 ± 1.4 to 25.4 ± 3.8 d. Administration of 20 μg MZ-J-7-118, sc, twice a day significantly (P < 0.05) decreased HEC-1A growth, as evidenced by a 57.9{\%} decrease in tumor volume, a 50.7{\%} reduction in tumor weight, and the extension of tumor doubling time from 17.5 ± 2.8 to 36.4 ± 6.5 d. Therapy with GHRH antagonists significantly decreased serum IGF-I levels in experiment 1, and significantly increased tumoral IGF-I levels in experiment 2 in treated mice. Levels of IGF-II and vascular endothelial growth factor-A in tumors were not changed. Specific high affinity binding sites for GHRH were found on HEC-1A tumor membranes using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42. MZ-J-7-118 displaced radiolabeled JV-1-42 with an IC50 of 0.13 ± 0.04 nM. The expression of mRNA for GHRH and splice variants of the GHRH receptor in HEC-1A tumors was demonstrated by real-time RT-PCR analysis. HEC-1A cells cultured in vitro secreted GHRH into the medium. The GHRH antagonist MZ-J-7-118 inhibited the growth of HEC-1A cells in vitro. Our results indicate that GHRH antagonists can reduce the growth of human endometrial cancer and could be used as an alternative adjuvant therapy for the management of endometrial cancer.",
author = "Engel, {J{\"o}rg B.} and Gunhild Keller and Schally, {Andrew V} and Toller, {Gabor L.} and Kate Groot and Alexandre Havt and Patricia Armatis and Marta Zarandi and Varga, {Jozsef L.} and Gabor Halmos",
year = "2005",
month = "6",
day = "1",
doi = "10.1210/jc.2004-2179",
language = "English",
volume = "90",
pages = "3614--3621",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone

AU - Engel, Jörg B.

AU - Keller, Gunhild

AU - Schally, Andrew V

AU - Toller, Gabor L.

AU - Groot, Kate

AU - Havt, Alexandre

AU - Armatis, Patricia

AU - Zarandi, Marta

AU - Varga, Jozsef L.

AU - Halmos, Gabor

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Antagonists of GHRH are being developed for the treatment of various cancers. In this study we investigated in vivo and in vitro the effects of the GHRH antagonist MZ-J-7-118 and its mechanism of action in HEC-1A human endometrial cancer. Treatment of nude mice bearing HEC-1A xenografts with 10 μg/d MZ-J-7-118 for 6 wk significantly inhibited the volume of HEC-1A tumors by 43%, tumor weight by 40% compared with controls and prolonged the tumor doubling time from 18.7 ± 1.4 to 25.4 ± 3.8 d. Administration of 20 μg MZ-J-7-118, sc, twice a day significantly (P < 0.05) decreased HEC-1A growth, as evidenced by a 57.9% decrease in tumor volume, a 50.7% reduction in tumor weight, and the extension of tumor doubling time from 17.5 ± 2.8 to 36.4 ± 6.5 d. Therapy with GHRH antagonists significantly decreased serum IGF-I levels in experiment 1, and significantly increased tumoral IGF-I levels in experiment 2 in treated mice. Levels of IGF-II and vascular endothelial growth factor-A in tumors were not changed. Specific high affinity binding sites for GHRH were found on HEC-1A tumor membranes using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42. MZ-J-7-118 displaced radiolabeled JV-1-42 with an IC50 of 0.13 ± 0.04 nM. The expression of mRNA for GHRH and splice variants of the GHRH receptor in HEC-1A tumors was demonstrated by real-time RT-PCR analysis. HEC-1A cells cultured in vitro secreted GHRH into the medium. The GHRH antagonist MZ-J-7-118 inhibited the growth of HEC-1A cells in vitro. Our results indicate that GHRH antagonists can reduce the growth of human endometrial cancer and could be used as an alternative adjuvant therapy for the management of endometrial cancer.

AB - Antagonists of GHRH are being developed for the treatment of various cancers. In this study we investigated in vivo and in vitro the effects of the GHRH antagonist MZ-J-7-118 and its mechanism of action in HEC-1A human endometrial cancer. Treatment of nude mice bearing HEC-1A xenografts with 10 μg/d MZ-J-7-118 for 6 wk significantly inhibited the volume of HEC-1A tumors by 43%, tumor weight by 40% compared with controls and prolonged the tumor doubling time from 18.7 ± 1.4 to 25.4 ± 3.8 d. Administration of 20 μg MZ-J-7-118, sc, twice a day significantly (P < 0.05) decreased HEC-1A growth, as evidenced by a 57.9% decrease in tumor volume, a 50.7% reduction in tumor weight, and the extension of tumor doubling time from 17.5 ± 2.8 to 36.4 ± 6.5 d. Therapy with GHRH antagonists significantly decreased serum IGF-I levels in experiment 1, and significantly increased tumoral IGF-I levels in experiment 2 in treated mice. Levels of IGF-II and vascular endothelial growth factor-A in tumors were not changed. Specific high affinity binding sites for GHRH were found on HEC-1A tumor membranes using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42. MZ-J-7-118 displaced radiolabeled JV-1-42 with an IC50 of 0.13 ± 0.04 nM. The expression of mRNA for GHRH and splice variants of the GHRH receptor in HEC-1A tumors was demonstrated by real-time RT-PCR analysis. HEC-1A cells cultured in vitro secreted GHRH into the medium. The GHRH antagonist MZ-J-7-118 inhibited the growth of HEC-1A cells in vitro. Our results indicate that GHRH antagonists can reduce the growth of human endometrial cancer and could be used as an alternative adjuvant therapy for the management of endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=21244491227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244491227&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-2179

DO - 10.1210/jc.2004-2179

M3 - Article

VL - 90

SP - 3614

EP - 3621

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -